Interleukin-31 at the neuroimmune interface of pruritus and dermatitis
白介素 31 在瘙痒和皮炎神经免疫界面的作用
基本信息
- 批准号:10240316
- 负责人:
- 金额:$ 17.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-25 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAddressAdultAdvisory CommitteesAffectAfferent NeuronsAfferent PathwaysAllelesAllergensAlopeciaAnimalsAtopic DermatitisAwardBehaviorBiologicalBiologyCD4 Positive T LymphocytesCaliforniaCellsChildChloroquineClinicalClinical TrialsCommunicationCouplesCutaneousDataDermatitisDermatologistDevelopmentDevelopment PlansDoctor of PhilosophyElementsEngineeringEnvironmentExanthemaExcoriationFoundationsFunctional disorderFutureGeneticGenetic EpistasisGoalsHTR2A geneHematopoieticHistamineImmuneImmune responseImmune systemInflammationInflammation MediatorsInflammatoryInterleukin-13Interleukin-4InterleukinsKnock-inLinkMapsMediatingMediator of activation proteinMentorshipMissionModelingMolecularMouse StrainsMusNational Institute of Arthritis and Musculoskeletal and Skin DiseasesNerveNervous system structureNeurogenic InflammationNeuroimmuneNeuronsNeurosciencesPAR-2 ReceptorPainPathway interactionsPatient CarePatientsPatternPeptide HydrolasesPeripheralPhysiciansPopulationPostdoctoral FellowProductionPruritusRecombinant InterleukinsReporterResearchResourcesSan FranciscoScientistSensorySignal TransductionSkinSourceT-LymphocyteTRPV1 geneTestingTherapeuticTherapeutic antibodiesTissuesTrainingTransgenic AnimalsTransgenic OrganismsUniversitiesafferent nerveatopybehavior influencebehavioral responsecareer developmentcell typechronic inflammatory skinchronic itchcytokineeffective therapyeffector T celleosinophilexperimental studyimprovedin vivomast cellmouse geneticsmouse modelmultidisciplinaryneurotoxicnoveloverexpressionpsychosocialreceptorresponseskin disordertool
项目摘要
PROJECT SUMMARY/ABSTRACT
Despite the clinical and psychosocial burden of itch in atopic dermatitis (AD), effective treatment options
are limited. Interleukin-31 (IL-31), an inflammatory factor produced by skin T cells, has emerged as a powerful
mediator of both itch and rash. When administered to skin, IL-31 can trigger dermatitis and activate cutaneous
afferent sensory nerves to drive scratching behavior. Therapeutic antibodies directed against IL-31 and its
receptor, IL31RA, have shown promise in clinical trials for AD and chronic pruritus. Yet fundamental questions
about IL-31 biology remain. Which cells make IL-31? What pathways does IL-31 actuate in sensory afferent
neurons? How do IL-31 signals integrate with other pruritogenic pathways in the context of inflammation?
Improved definitions of the sources, pathways, and effector functions of IL-31 will substantially advance
mechanistic understanding of the links between inflammation and itch.
Dr. Fassett’s long-term research goal is to elucidate cellular and molecular mechanisms responsible for
atopy-associated pruritus. The objective of this proposal is to use genetic mouse models to address the in vivo
biology of IL-31 by examining the effects of endogenous IL-31 on cutaneous inflammation and pruritus sensory
pathways. Dr. Fassett’s central hypothesis is that IL-31 couples itch and rash via its combined effects on
pruritoceptive afferent pathways and cutaneous Th2 cytokine-mediated inflammation. Dr. Fassett will test this
hypothesis using three specific aims. In Aim 1, Dr. Fassett will use novel IL31-deficient animals and IL31-
tdTomato reporter animals to determine how multiple IL-31 source cell types functionally impact cutaneous Th2
inflammation in vivo. In Aim 2, she will elucidate the contribution of IL-31:IL31RA to atopy-associated
pruritoceptive pathways including itch sensation and neurogenic inflammation. In Aim 3, she will determine how
IL-31 alters afferent responses to other pruritogens, including Th2 cytokines. This project is relevant to the
mission of NIAMS because it explores the mechanism of action of IL-31, a biologic target of potentially great
therapeutic value for atopic dermatitis and for pruritus associated with other inflammatory skin diseases.
Dr. Fassett is an MD PhD-trained Dermatologist working as a post-doctoral research fellow at the University
of California, San Francisco. She is applying for a K08 Award to support her goal of becoming an independent
physician scientist. UCSF’s exceptional training environment will support her efforts. Critical elements of her
career development plan include mentorship by Dr. Mark Ansel, expert in cytokine biology and Th2 inflammation;;
co-mentorship by Dr. Allan Basbaum, expert in pain and itch;; guidance by a multidisciplinary advisory committee
including senior physician-scientists;; coursework in advanced experimental neuroscience;; and professional
development activities. Taken together, this career development plan will provide Dr. Fassett with a strong
foundation on which to build her growing expertise in the neuroimmune pathways that couple itch and rash.
项目概要/摘要
尽管特应性皮炎(AD)瘙痒会带来临床和社会心理负担,但有效的治疗选择
白细胞介素 31 (IL-31) 是一种由皮肤 T 细胞产生的炎症因子,现已成为一种强大的药物。
IL-31 是瘙痒和皮疹的介质。当施用到皮肤上时,IL-31 可以引发皮炎并激活皮肤。
传入感觉神经驱动针对 IL-31 及其抓挠行为的治疗性抗体。
受体 IL31RA 在治疗 AD 和慢性瘙痒症的临床试验中显示出了前景。
关于 IL-31 的生物学特性。哪些细胞会产生 IL-31?IL-31 在感觉传入中激活哪些途径?
在炎症情况下,IL-31 信号如何与其他致痒途径整合?
IL-31 的来源、途径和效应子功能的定义的改进将大大推进
对炎症和瘙痒之间联系的机制理解。
法塞特博士的长期研究目标是阐明负责的细胞和分子机制
该提案的目的是使用遗传小鼠模型来解决体内的问题。
通过检查内源性 IL-31 对皮肤炎症和瘙痒感觉的影响来研究 IL-31 的生物学
Fassett 博士的中心假设是 IL-31 通过其对瘙痒和皮疹的综合作用。
Fassett 博士将测试瘙痒传入通路和皮肤 Th2 细胞因子介导的炎症。
使用三个特定目标的假设 在目标 1 中,Fassett 博士将使用新型 IL31 缺陷动物和 IL31-
tdTomato 报告动物确定多种 IL-31 源细胞类型如何在功能上影响皮肤 Th2
在目标 2 中,她将阐明 IL-31:IL31RA 对特应性相关的作用。
在目标 3 中,她将确定瘙痒感受途径,包括瘙痒感和神经源性炎症。
IL-31 改变对其他瘙痒原(包括 Th2 细胞因子)的传入反应。
NIAMS 的使命是因为它探索了 IL-31 的作用机制,IL-31 是一个具有潜在巨大潜力的生物靶标。
对特应性皮炎和与其他炎症性皮肤病相关的瘙痒具有治疗价值。
Fassett 博士是一位医学博士训练有素的皮肤科医生,在该大学担任博士后研究员
她正在申请 K08 奖,以支持她成为独立人士的目标。
加州大学旧金山分校卓越的培训环境将支持她的努力。
职业发展计划包括细胞因子生物学和 Th2 炎症专家 Mark Ansel 博士的指导;
由疼痛和瘙痒专家 Allan Basbaum 博士共同指导;由多学科咨询委员会提供指导;
包括高级医师科学家;;以及高级实验神经科学课程;
总而言之,该职业发展计划将为法塞特博士提供强大的支持。
在此基础上,她在瘙痒和皮疹相关的神经免疫途径方面不断积累专业知识。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marlys S Fassett其他文献
Marlys S Fassett的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marlys S Fassett', 18)}}的其他基金
Illuminating IL-31-producing cells in allergic skin disease
照亮过敏性皮肤病中产生 IL-31 的细胞
- 批准号:
10729476 - 财政年份:2023
- 资助金额:
$ 17.75万 - 项目类别:
Interleukin-31 at the neuroimmune interface of pruritus and dermatitis
白介素 31 在瘙痒和皮炎神经免疫界面的作用
- 批准号:
10025166 - 财政年份:2019
- 资助金额:
$ 17.75万 - 项目类别:
Interleukin-31 at the neuroimmune interface of pruritus and dermatitis
白介素 31 在瘙痒和皮炎神经免疫界面的作用
- 批准号:
10470809 - 财政年份:2019
- 资助金额:
$ 17.75万 - 项目类别:
Interleukin-31 at the neuroimmune interface of pruritus and dermatitis
白介素 31 在瘙痒和皮炎神经免疫界面的作用
- 批准号:
10684666 - 财政年份:2019
- 资助金额:
$ 17.75万 - 项目类别:
相似国自然基金
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
相似海外基金
The role of dendritic cells in heart valve extracellular matrix remodeling, homeostasis, and disease
树突状细胞在心脏瓣膜细胞外基质重塑、稳态和疾病中的作用
- 批准号:
10672638 - 财政年份:2023
- 资助金额:
$ 17.75万 - 项目类别:
A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma
一种用于治疗 B 系急性淋巴细胞白血病/淋巴瘤的新型 VpreB1 抗体药物偶联物
- 批准号:
10651082 - 财政年份:2023
- 资助金额:
$ 17.75万 - 项目类别:
Genetic and molecular mechanisms of Xbp-1 mediated salivary gland development and differentiation
Xbp-1介导唾液腺发育和分化的遗传和分子机制
- 批准号:
10678146 - 财政年份:2023
- 资助金额:
$ 17.75万 - 项目类别:
Neural pathways for obesity development by AgRP neurons
AgRP 神经元导致肥胖发展的神经通路
- 批准号:
10681993 - 财政年份:2023
- 资助金额:
$ 17.75万 - 项目类别:
Mitochondrial proton leak and neonatal brain injury
线粒体质子泄漏与新生儿脑损伤
- 批准号:
10724518 - 财政年份:2023
- 资助金额:
$ 17.75万 - 项目类别: